Vestor Capital’s Sarepta Therapeutics SRPT Stock Holding History

Vestor Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,472	Closed	-$1.88M	–	261
2023 Q3	$1.88M	Buy	+15,472	New	+$1.75M	0.2%	78

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vestor Capital's SRPT Position: Q4 2023 in Review

Vestor Capital sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 15,472 shares — an estimated $1.88M sold.

Vestor Capital first reported a position in SRPT in Q3 2023 and held it in 1 quarter. The position peaked at $1.88M in Q3 2023. 395 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

Vestor Capital reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
Vestor Capital sold 15,472 Sarepta Therapeutics shares in Q4 2023, an estimated $1.88M.
Vestor Capital first reported a position in Sarepta Therapeutics in Q3 2023 and held it in 1 quarter.
Vestor Capital's Sarepta Therapeutics position peaked at $1.88M in Q3 2023.
395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Vestor Capital's 13F filing for Q4 2023, filed 7 Feb 2024.